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Recent advancements in medical genetics and molecular biology are 
reflected in the modern understanding and approach to colorectal carcinoma 
(CRC). Understanding the cellular mechanisms and mutational patterns that 
promote carcinogenesis could enhance the predictive accuracy of the TNM 
classification. Furthermore, this will allow for a much more documented 
stratification and tailored oncological treatment.  This paper presents an 
illustrative case of a relatively young patient (50 years old) with no family 
history of cancer who was diagnosed with four synchronous gastrointestinal 
(GI) adenocarcinomas displaying a wild type P53, negative BRAF testing, 
and mutated MLH1 and PMS2 proteins. This case report contributes to the 
relevant literature with a concise review of the role of micro-satellite 
instability (MSI), chromosomal instability (CIN), and CpG island 
methylator phenotype (CIMP) in carcinogenesis, hereditary and sporadic 
gastrointestinal cancers, a discussion over the importance of molecular sub-
typing in predicting long term outcomes and choosing the most suitable 
adjuvant treatment regimen.   
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Recent advancements in medical genetics and 
molecular biology are reflected in the modern 
understanding and approach to colorectal carcinoma 
(CRC). Although the intricacies of the subtle mechanisms 
of molecular carcinogenes are not yet fully clarified, 
emerging research suggests that similar to breast cancer, 
stratification of the patients based on molecular 
characteristics or subtypes of CRC could influence 
survival, response to treatment, and loco-regional 
recurrences.  
Nowadays it is unanimously agreed that colonic 
carcinogenesis is multifactorial and multi-phased. Based 
on proven causal links between etiologic factors, genetic 
and epigenetic mutations, and prognostic factors, we 
believe that representative cases of multiple primary 
familial or hereditary CRC ought to be popularized in 
order to reiterate the importance of screening and 
genetic counseling in one of the most preventable 
malignancies of our times.  
This paper presents an illustrative case of a relatively 
young patient (50 years old) with no family history of 
cancer who was diagnosed with four synchronous 
gastrointestinal (GI) adenocarcinomas displaying multiple 
mutational patterns. This case report contributes to the 
relevant literature with a concise review of the role of 
micro-satellite instability (MSI), chromosomal instability 
(CIN), and CpG island methylator phenotype (CIMP) in 
carcinogenesis, hereditary and sporadic gastrointestinal 
cancers, and a discussion of the importance of molecular 
sub-typing in predicting long term outcomes and choosing 
the most suitable adjuvant treatment regimen. 
Case presentation 
A 50 years old patient with no previous personal or 
family medical history and no associated comorbidities 
presented with recurrent left flank abdominal discomfort to 
his general practice doctor who, after an unremarkable 
clinical examination, recommended a renal ultrasound 
(USS), a complete blood count (CBC), and a urine sample. 
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No abnormality was detected except for an incidental renal 
cyst of 25/14mm on the right side. Despite these, having a 
high index of suspicion of a kidney condition, the GP 
ordered a CT scan for further characterization of the renal 
tract. The CT exam unexpectedly revealed circumferential 
thickening of the splenic flexure extending over 9 
centimeters in length, with intense iodophilia, adjacent fat 
stranding, and supracentrimetric perilesional lymph nodes 
(Figure 1). An additional endoluminal area in the caecum 
was described, but with minimal contrast enhancement and 
nonspecific features (Figure 2). No lesions suggestive of 
liver or bony metastases were reported.  
 
Figure 1. CT scan: splenic flexure tumoral mass, with 
severe narrowing of the lumen  
 
Figure 2. CT scan: caecal mass and the ileocaceal-valve 
The patient was admitted to our institution with the 
presumptive diagnosis of colorectal cancer – possible 
synchronous cecal and splenic flexure tumors—for further 
investigation and treatment. The clinical exam did not 
reveal significant pathological features, the main 
subjective sign was transient left hypocondrum and left 
flank pain of moderate intensity, and intestinal transit 
disturbances, with predominant constipation. The 
laboratory tests were normal, except mild anemia (Hb 
12mg/dl). For completion of the preoperative evaluation, a 
thoracic CT scan (no pulmonary abnormality detected) and 
a colonoscopy were performed. The endoscopic 
examination revealed a small polypoid lesion in the 
sigmoid colon and a circumferential tumor at the splenic 
flexure which could not be negotiated. Biopsies showed 
moderately differentiated adenocarcinoma (G2) NOS type 
for both lesions.  
After informed consent was signed, the patient 
underwent surgery with a planned exploratory laparotomy 
+/- proceed and repeat on table colonoscopy for a full 
assessment of the bowel. During the macroscopic intra-
abdominal assessment, a supracentrimetric lesion was 
identified on the greater curvature of the stomach (antral 
area), with no connection to the splenic flexure mass.  
After a second unsuccessful endoscopic attempt to pass 
above the splenic flexure lesion, a minimal colotomy was 
performed proximal to the tumor and a purse-string tie was 
placed to ensure air-tightness around the colonoscope. 
Completion of the colonoscopy revealed a caecal mass 
from which frozen sections biopsies confirmed 
adenocarcinoma. At this stage, we have identified three 
synchronous colonic adenocarcinomas and a suspicious 
gastric lesion for which endoscopic frozen sections 
confirmed moderately differentiated adenocarcinoma.  
Total colectomy with complete mesocolic excision (CME) 
and D1 gastrectomy were performed. The postoperative 
course was uneventful, with discharge after a week.  
The ensuing commented images show the 
histopathological features of the tumors. An additional 
panel of surrogate gene assessment using IHC 
demonstrates a wild type of p53, the absence of MLH1 and 
PMS2 proteins, suggesting either a germ line mutation or 
inhibition by epigenetic modification (CIMP). Since CIMP 
mutations are associated with BRAF mutations, we believe 
that a negative BRAF testing is highly indicative of a 
possible Lynch syndrome. A positive diagnosis of non-
polyposis hereditary colon cancer (HNPCC) means a 50% 
risk for the direct descendants to develop the disease since 
it is transmitted in an autosomal dominant manner.  
All 4 tumors are solid-type proliferations, with weak-
moderate differentiation, with ulcerated surface, and 
showing important areas of necrosis and intra-tumoral 
hemorrhage, as well as a rich inflammatory infiltrate 
formed by polymorphonuclear, lymphocytes and large 
histiocytes, which partially shield tumor proliferation at the 
level of the invasion front. The lymph nodes analyzed do 
not show tumor invasion, but show non-specific chronic 
inflammatory features. 
Other histopathological findings were adenomatous 
colonic polyp with low grade intraepithelial dysplasia and 
chronic non-atrophic gastritis with moderate inflammatory 
activity and intestinal focal metaplasia. 
Histopathological characteristics of the 4 synchronous 
tumors, in a young patient 50 years old, require the 
continuation of investigations by immunohistochemical 
testing to complete the diagnosis and establish a possible 
syndromic classification, such as Lynch Syndrome.     




Figure 3 (A, B). Histopathological aspects of the 4 
synchronous tumors (HE, x10). 
 A: moderately differentiated tubular gastric adenocarcinoma 
(G2), intestinal type (Lauren classification), stage IIB 
(pT4N0Mx), with cell proliferation with medium and large 
cells, with moderate cyto-nuclear atypia, which infiltrates the 
entire gastric wall passing the serosa. Tumor cells show 
atypical mitotic figures, some being multipolar, with severe 
dyskaryosis. 
 B: moderately differentiated colonic (cecal) adenocarcinoma 
(G2), stage IIA (pT3NoMx): large, atypical cells, with 
moderate cyto-nuclear pleomorphism that form numerous 
irregular glandular structures, of various sizes, with infiltrative 
and destructive character on adjacent structures, without 
invading the serosa. Bd1 tumor budding; absence of perineural 
invasion or angio-lymphatic tumor emboli. 
 
Figure 3 (C, D). Histopathological aspects of the 4 
synchronous tumors (HE, x10). 
C:  poorly differentiated colonic adenocarcinoma (splenic 
flexure) (G3), stage IIA (pT3pN0Mx): numerous cellular 
atypia, cyto-nuclear pleomorphism, rare small glandular and 
pseudo-glandular structures with irregular appearance, typical 
and atypical mitotic figures, without serous infiltration, with 
Bd3 tumor budding and perineural invasion elements and 
lympho-vascular emboli. 
D: colonic adenocarcinoma (sigmoid), moderately 
differentiated G2, stage IIB (pT3pN0Mx), with mucinous 
differentiation (in 15% of cases), with extracellular mucin 
lakes with basophilic tint containing glandular fragments and 
groups of tumor cells, Bd2 tumor budding and perineuronal 
invasion and vascular-lymphatic emboli. 
The immunohistochemical expression pattern 
performed for the 4 synchronous tumors completes and 
confirms the initial diagnosis and suggests high 
microsatellite instability in the MLH1 / PMS2 gene for all 
tumors and MSH2 / MSH6 for the sigmoid one. The wild-
type expression of p53 is a favorable prognostic element, 
as is the absence of Her2neu expression in the gastric tumor 
(Table 1). 
 
Table 1. Immunohistochemical MMR pattern in the 4 synchronous tumors 
 Gastric tumor Cecal tumor Splenic flexure tumor Sigmoid tumor 
MLH1 
-  -  -  -  
MSH2 
+  +  +  -  
MSH6 
+  +  +  -  
PMS2 
-  -  -   -  
P53 
Wild-type 
   
Wild-type 
   
Wild-type 
   
Wild-type 
   
Her2neu 
 -  
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BRAF V600 mutation was further tested regarding the 
differentiation of sporadic colorectal cancer with high 
microsatellite instability (MSI-H) from hereditary non-
polyposis colorectal carcinoma (HNPCC) or Lynch 
syndrome and the result was negative, suggesting a 
mutational pattern rather than inhibition by 
hypermethylation of MLH1. 
Discussions 
Colorectal cancer is a major cause of morbidity and 
mortality in the world and in Romania. Synchronous 
malignancies were first described by Billroth in 1889. The 
diagnostic criteria were developed in 1932 by Warren and 
Gates and set out the following conditions: i) the tumors 
must have histopathological confirmation of malignancy; 
ii) they must be anatomically distinct (be separated from 
each other by at least four cm of healthy tissue); iii) one 
tumor must not be the metastasis of the other; iv) they must 
be diagnosed simultaneously or at a maximum interval of 
one year from each other. [1-4] The incidence of 
synchronous tumors varies, in different studies, between 
1.8 and 12.4%. [4] The frequency with which adenomatous 
polyps are associated with colorectal cancer is 15-50%. 
Known risk factors for synchronous tumors are male sex, 
family history, age, and the presence of synchronous 
adenomas. [2,3] Predisposing conditions are familial 
adenomatous polyposis, inflammatory bowel disease, and 
hereditary non-polyposis cancer (Lynch syndrome) [4-7]. 
Preoperative evaluation of the entire colon in patients 
with colorectal cancer is important, but not always 
possible. Because of this, proximal lesions synchronous 
with the initial tumor may be missed. This can change the 
intraoperative treatment plan or even cause a reoperation. 
The undetected lesions (polyps or cancers) continue their 
evolution and, at the time of subsequent diagnosis, they 
appear in an advanced stage or even surgically outdated. 
Synchronous colorectal cancers have rarely been studied in 
large cohorts; however, the analysis of synchronous tumors 
can provide special, unique data on the pathogenesis of 
colon and rectal cancer [4,7]. 
Molecular events associated with colon carcinogenesis 
During malignancy, the colonic epithelium undergoes 
a series of genetic changes that are reflected in histological 
changes. Genetic mutations occur long before clinically 
obvious lesions. In many cancers, the cells acquire 
characteristics that favor malignant transformation, but do 
not produce visible morphological changes, creating only 
a predisposition for cancer.[8] The modified cells form 
areas of mucosa prone to malignancy; the process is called 
"field cancerization" and can lead to synchronous tumors. 
There are three main recognized carcinogenic 
mechanisms: chromosomal instability (CIN), micro-
satellite instability (MI), involved with more than 95% of 
HNPCC’s, and aberrant DNA methylation (CIMP). 
Most malignancies (70-75%) occur as a result of events 
that cause chromosomal instability (CIN) and progress to 
the suppressive pathway. The other colon cancers are 
caused by hypermethylation of the genes (the methylating 
phenotype of the CpG-CIMP islands) and evolve in the 
serum pathway; some of them have microsatellite 
instability (MSI), and the development of the latter takes 
place on the mutant path. One of the earliest changes in 
both oncogenesis pathways (MSI and CIN) is the loss of 
APC gene function, which predisposes people with germ-
line mutations in APC to develop colon cancer [6-9].  
Approximately 15% of colorectal adenocarcinomas are 
associated with MSI: 2.5% coming from a genetic 
inheritance and 12.5% being sporadic. [10] 
Mismatch repair (MMR) genes and Microsatellite 
instability (MSI) 
Microsatellite instability (MSI) is due to altered 
expression of MMR genes (mismatch repair), involved in 
the processes of recognition and repair of microsatellite 
errors during DNA synthesis to maintain genomic stability. 
There are 4 MMR genes and their encoded proteins, which 
form heterodimers 2 by 2: MLH1 / PMS2 and MSH2 / 
MSH6. Inactivation of MLH1 and MSH2 account for over 
90% of deficient MMR cases. If any of the four major 
proteins (MSH2, MLH1, MSH6, or PMS2) is functionally 
inactive, mismatches are not repaired. A defective DNA 
MMR system increases the mutation rate and makes the 
cell vulnerable to mutations in genes controlling cell 
growth (including tumor suppressor genes and oncogenes), 
resulting in an elevated cancer risk. [11,12] 
Immunohistochemical analysis revealed that when 
MLH1 or MSH2 is nonfunctional, their corresponding 
peers will also appear negative, as they disintegrate without 
their obligatory partners. In contrast, inactivation of MSH6 
or PMS2 does not lead to absence of MSH2, respectively 
MLH1, as these proteins can dimerize also with other 
proteins, for example MLH3[11]. 
Sporadic MSI is caused more frequently by epigenetic 
silencing of the MLH1 promoter by methylation, which is 
associated with a somatic BRAF V600E mutation. 
Hereditary MSI commonly happens due to autosomal 
dominant mutations in MMR. Lynch syndrome is 
associated in 90% of cases with MLH1 or MSH2 mutations 
[13]. 
In the presented case, the immunohistochemical pattern 
associated with the absence of the BRAF V600 mutation is 
suggestive of the MLH1 mutation in all 4 tumors, and, in 
addition, of MSH2 in the sigmoid tumor. 
Testing the mismatch repair genes (MMR) profile by 
immunohistochemistry is particularly important for 
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understanding the mechanism of carcinogenesis, planning 
cancer treatment, and evaluating the prognosis in 
synchronous digestive cancers. [14] The criteria for 
recommending testing for MSI are, according to the Dutch 
guideline for MSI testing (http://www.oncoline.nl): 
1. CRC or endometrial carcinoma before the age of 50 
years. 
2. A second CRC before the age of 70 years. 
3. CRC before the age of 70 years AND another 
synchronous or previous Lynch Syndrome associated 
tumor 
Clinical and prognostic features of MSI-H colorectal 
tumors 
Cancers associated with MSI-H have special 
characteristics from a histopathological point of view; they 
are generally adenocarcinomas with medium-weak 
differentiation, with possible mucinous component and 
important associated inflammatory lymphocytic infiltrate. 
They are predominantly located on the right side of the 
colon [15,16]. 
Patients with MSI-H tumors have been associated with 
a more favorable prognosis compared to patients with MSI-
L or MSS tumors, a significantly lower likelihood of 
metastasizing to regional lymph and distant organs [17,18]. 
Given our current level of understanding, this favorable 
prognosis could not be fully explained only by molecular 
mechanisms, but studies correlate better survival with the 
presence of lymphocytic infiltration seen in MSI-H tumors, 
an expression of an enhanced host immune response 
invoked by the presence of numerous mutated products 
[19-22].  
Others have also suggested that the enormous 
mutational burden resulting from loss of MMR activity 
may be self-limiting in that essential cell functions may be 
hindered [16,21-23]. Regarding the response to 5-FU, it is 
considered that in stage II chemotherapy is not necessary 
for MSI-H tumors. The favorable prognosis and the 
evidence of lack of benefit from 5-FU based adjuvant 
chemotherapy in stage II CRC patients with deficient 
MMR indicate that these patients should not receive 
adjuvant chemotherapy. In stage III CRC, however, 
patients with deficient MMR cancers treated with adjuvant 
5-FU had better outcomes. In stage III colon cancer 
patients, oxaliplatin combined with 5-FU is the current 
standard of care for adjuvant chemotherapy. In contrast to 
5-FU, sensitivity to oxaliplatin was independent of the 
MMR system in CRC cell lines [24-26]. The absence of 
BRAF mutation expression is a favorable prognostic factor 
[27,28]. 
The particularity of the case resides in the absence of 
any family history of CRC and the lack of digestive 
symptoms. These led to the accidental detection of the 
colon tumors by CT examination, followed by subsequent 
exploration, but without paying preoperatory attention to 
upper digestive tract [29]. However, rare “de novo” cases 
of Lynch syndrome have been reported and prompted early 
familial screening potentially preventing CRC associated 
morbidity.  
Incomplete possibilities of preoperative assessment, 
due to the stenotic behavior of splenic flexure tumor, led to 
intraoperative change of the surgical plan. Although bulky, 
tumors had histopathological and immunohistochemical 
features which were statistically associated with favorable 
prognosis. Regular follow-up in the surgical department is 
necessary for screening of recurrent tumors or 
metachronous cancers. [30-32]. 
Highlights 
✓ Careful pre- and intraoperative evaluation of patients 
with suspected synchronous cancers is particularly 
important in therapeutic planning. 
✓ MSI represents a promising disease marker for 
colorectal cancers because of the favorable prognosis 
associated with MSI-H and particularities of 
oncological management. 
Conclusions 
Careful pre- and intraoperative evaluation of patients 
with suspected synchronous cancers is of paramount 
importance in therapeutic planning. Additionally, 
employment of IHC testing for surrogate gene mutations 
identification represents a promising complementary tool 
for improvement of prognostic assessment and tailored 
oncological treatment.  
Although more than 75% of colorectal cancers are 
sporadic, identification of familial and hereditary CRC 
could increase the efficacy of screening programs and 
reduce the economic pressure exerted on health systems 
worldwide. The perspective of developing new treatment 
options and optimized guidelines for CRC can become a 
reality only by incorporating gene assessment and ultra- 
stratification of patients.  
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